ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani Sells 16,669 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 16,669 shares of the company’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $66.10, for a total transaction of $1,101,820.90. Following the completion of the sale, the chief executive officer now directly owns 377,505 shares in the company, valued at $24,953,080.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Nikhil Lalwani also recently made the following trade(s):

• On Friday, March 8th, Nikhil Lalwani sold 16,292 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $67.13, for a total transaction of $1,093,681.96.
• On Wednesday, March 6th, Nikhil Lalwani sold 28,965 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.52, for a total transaction of $1,897,786.80.

ANI Pharmaceuticals Trading Down 1.6 %

ANIP stock traded down $1.05 during trading on Thursday, reaching $63.77. 132,119 shares of the stock were exchanged, compared to its average volume of 137,656. The company has a current ratio of 3.95, a quick ratio of 3.12 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average price of $66.96 and a 200-day moving average price of $59.63. ANI Pharmaceuticals, Inc. has a 1 year low of $43.32 and a 1 year high of $70.81. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of 40.51 and a beta of 0.80.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. The company had revenue of $131.65 million for the quarter, compared to the consensus estimate of $123.02 million. On average, research analysts predict that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp increased its position in shares of ANI Pharmaceuticals by 9.0% during the third quarter. Bank of New York Mellon Corp now owns 123,717 shares of the specialty pharmaceutical company’s stock valued at $7,183,000 after acquiring an additional 10,234 shares during the last quarter. New York State Teachers Retirement System increased its position in shares of ANI Pharmaceuticals by 0.9% during the third quarter. New York State Teachers Retirement System now owns 22,180 shares of the specialty pharmaceutical company’s stock valued at $1,288,000 after acquiring an additional 200 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of ANI Pharmaceuticals by 43.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,338 shares of the specialty pharmaceutical company’s stock valued at $194,000 after acquiring an additional 1,015 shares during the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of ANI Pharmaceuticals by 9.2% during the third quarter. Oregon Public Employees Retirement Fund now owns 4,754 shares of the specialty pharmaceutical company’s stock valued at $276,000 after acquiring an additional 400 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of ANI Pharmaceuticals by 41.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,380 shares of the specialty pharmaceutical company’s stock valued at $196,000 after acquiring an additional 989 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ANIP has been the subject of a number of research analyst reports. Capital One Financial initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective for the company. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Guggenheim reiterated a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. Finally, HC Wainwright increased their target price on shares of ANI Pharmaceuticals from $83.00 to $87.00 and gave the company a “buy” rating in a research report on Monday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $81.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.